KFF links each drugs NDC in the dataset to a drug class using the World Health Organizations (WHO) Anatomical Therapeutic Chemical (ATC) classification system
As we have seen with GLP-1 drugs, once a therapy demonstrates both biological efficacy and real-world impact, adoption can accelerate very quickly. Whether through stem cell activation, immune modulation, reformulated legacy drugs, or regenerative medicine, the next generation of hair loss therapies is no longer chasing incremental improvement
Abstract We conducted a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database (2005 Q22024 Q3) to evaluate neurological adverse events (NAEs) associated with six glucagon-like peptide-1 receptor agonists (GLP-1 RAs): exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, and tirzepatide
To summarize, the causal effect of GLP1Rs dual- and tri-peptidic agonists on MASLD and its risk factors was reliable and robust
Men with a personal or strong family history of medullary thyroid cancer should avoid GLP-1 agonists due to animal study signals, though human data remain reassuring
Retatrutide is typically supplied as a lyophilized powder for maximum stability
